青岛大学学报（医学版）2023，Vol.59Issue(6)：880-885,6.DOI:10.11712/jms.2096-5532.2023.59.180
EGFR-TKIs联合血管生成抑制剂治疗晚期NSCLC效果meta分析
EFFICACY AND SAFETY OF EPITHELIAL GROWTH FACTOR RECEPTOR-TYROSINE KINASE INHIBITORS USED ALONE OR IN COMBINATION WITH ANGIOGENESIS INHIBITORS IN TREATMENT OF ADVANCED NON-SMALL CELL LUNG CANCER:A META-ANALYSIS
摘要
Abstract
Objective To investigate whether epidermal growth factor receptor-tyrosine kinase receptor inhibitors(EGFR-TKIs)used alone or in combination with angiogenesis inhibitors can bring treatment benefits to non-small cell lung cancer(NSCLC)patients with epidermal growth factor receptor(EGFR)mutation.Methods With the key words including"carcino-ma","non-small cell lung",and"angiogenesis inhibitors",PubMed,Embase,the Cochrane Library,American Society of Clinical Oncology database,European Society of Medical Oncology database,Wanfang Data,and CNKI were searched for randomized con-trolled trials and prospective cohort studies on EGFR-TKIs with or without angiogenesis inhibitors as the first-line treatment and as the second-or third-line treatment for advanced EGFR-mutated NSCLC published from January 2012 to December 2022.Outcome measures included progression-free survival(PFS)and overall survival(OS).Results A total of 16 studies were included,with 1 816 patients in total.In the first-line treatment,combination therapy could prolong PFS compared with EGFR-TKIs monotherapy(HR=0.61,P<0.001),but there were no significant differences between the two groups in OS,objective response rate,and di-sease control rate(P>0.05),with more grade≥3 adverse events in the combination group.In the second-or third-line treatment,combination therapy failed to improve PFS(HR=1.24,P=0.14).Conclusion In the first-line treatment,combination therapy significantly prolongs PFS in EGFR-mutant NSCLC patients,but combination therapy does not bring benefits to PFS in the se-cond-or third-line treatment.关键词
癌,非小细胞肺/血管生成抑制剂/ErbB受体/Meta分析Key words
carcinoma,non-small-cell lung/angiogenesis inhibitors/ErbB receptors/Meta-analysis分类
临床医学引用本文复制引用
张林玲,殷俊,贾洪源..EGFR-TKIs联合血管生成抑制剂治疗晚期NSCLC效果meta分析[J].青岛大学学报（医学版）,2023,59(6):880-885,6.基金项目
吴阶平医学基金会临床科研专项资助基金(320.6750.2021-22-27) （320.6750.2021-22-27）
